Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Graft Versus Host Disease (GVHD): Likelihood of Approval
Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...
HRS-7085 by Jiangsu Hengrui Medicine for Inflammatory Bowel Disease: Likelihood of Approval
HRS-7085 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Inflammatory Bowel Disease. According to...
SHRA-1921 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
SHRA-1921 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Solid Tumor. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal...
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to...
HRS-5965 by Jiangsu Hengrui Medicine for IgA Nephropathy (Berger's Disease): Likelihood of Approval
HRS-5965 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for IgA Nephropathy (Berger's Disease). According...
Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Graft Versus Host Disease (GVHD): Likelihood of Approval
Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...
SHRA-1904 by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Solid Tumor. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...